Articles related to DIABETIC RETINOPATHY

A retinal specialist reviewing GLP-1 ocular safety evidence at the Retina World Congress concluded that current data do not support withholding therapy based on ocular risk alone, while recommending baseline retinal examination and closer monitoring in patients with preexisting severe diabetic retinopathy.

Bayer agreed to acquire Perfuse Therapeutics in a deal valued at up to $2.45 billion, gaining full rights to a phase 2 endothelin receptor antagonist for glaucoma and diabetic retinopathy.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.

Fewer than half of adults with diabetes at a Northern Uganda referral hospital had received an eye examination in the past five years, with education and disease awareness emerging as the strongest predictors of uptake.

OCT angiography revealed subclinical retinal and choroidal blood flow changes that correlated with disease severity across diabetic retinopathy, AMD, and central serous retinopathy in cited studies.

Tirzepatide use was associated with a little more than double the odds—115 percent—of developing PDR compared with those not on the medication, with most cases occurring in patients who already had mild retinal damage from diabetes.